Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

Herschorn, Sender; Stothers, Lynn; Carlson, Kevin; Egerdie, Blair; Gajewski, Jerzy B; Pommerville, Peter; Schulz, Jane; Radomski, Sidney; Drutz, Harold; Barkin, Jack; Paradiso-Hardy, Fran

Herschorn, Sender; Stothers, Lynn; Carlson, Kevin; Egerdie, Blair; Gajewski, Jerzy B; Pommerville, Peter; Schulz, Jane; Radomski, Sidney; Drutz, Harold; Barkin, Jack; Paradiso-Hardy, Fran.

Affiliation

Herschorn S; Department of Surgery/Urology, University of Toronto, Toronto, Ontario, Canada. s.herschorn@utoronto.ca

J Urol ; 183(5): 1892-8, 2010 May.

Article in En | MEDLINE | ID: mdl-20303119

Subject(s)

Mandelic Acids/administration & dosage; Muscarinic Antagonists/administration & dosage; Quinuclidines/administration & dosage; Tetrahydroisoquinolines/administration & dosage; Urinary Bladder, Overactive/drug therapy; Adult; Aged; Aged, 80 and over; Canada/epidemiology; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Mandelic Acids/adverse effects; Middle Aged; Muscarinic Antagonists/adverse effects; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Treatment Outcome; Xerostomia/chemically induced; Xerostomia/epidemiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinuclidines / Muscarinic Antagonists / Tetrahydroisoquinolines / Urinary Bladder, Overactive / Mandelic Acids Type of study: Clinical_trials / Incidence_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: J Urol Year: 2010 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google